Shareholding disclosure

GEFIM SPA

Declared position

10%

Threshold

Crossed upwards

Timeline

Published

13.04.2012

Transaction

—

Transfer date

11.04.2012

Voting rights breakdown

Voting rights acquired10%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAC4C00065

Beneficial owner

GEFIM SPA

Declared address

GEFIM SPA, 20122 MILANO

entity controlled for the 85,92% by GEFIM SPA

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

GEFIM SPA

Newron Pharmaceuticals S.p.A.13.04.2012TAC4C00065

Disclosure summary

GEFIM SPA disclosed a holding in Newron Pharmaceuticals S.p.A. on the acquisition side, published by SIX Exchange Regulation on 13.04.2012, at 10% of voting rights. Notice category: Single shareholder.

Disclosed position

10%

Voting rights acquired

Voting rights acquired10%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

GEFIM SPA disclosed a holding in Newron Pharmaceuticals S.p.A., published on 13.04.2012.

Publication date13.04.2012

Transfer date11.04.2012

Issuing companyNewron Pharmaceuticals S.p.A.

Beneficial ownerGEFIM SPA

Declared addressGEFIM SPA, 20122 MILANO

CategorySingle shareholder

Voting rights acquired10%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAC4C00065

Conditions

entity controlled for the 85,92% by GEFIM SPA

Source: SIX Exchange Regulation · Publication date: 13.04.2012

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open